AstraZeneca, AVEO Oncology form lung cancer collaboration
AVEO Oncology has announced the start of an immuno-oncology focused clinical collaboration with drug giant AstraZeneca (AZ).
Read More
Tag: Aveo
Novartis to hand back rights to Aveo’s AV-380
Novartis is intending to hand back rights to Aveo Oncology’s experimental antibody AV-380, which it acquired in August 2015 in a deal valued at at least $326 million.
Read More
- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
